Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
On July10, 2017, Flexion Therapeutics, Inc. issued a press release noting topics to be presented at its investor and analyst day event, including information with respect to its new FX101 Fluticasone ER development program. A copy of the press release is attached hereto as Exhibits 99.1 and incorporated by reference herein.
Item 9.01Financial Statements and Exhibits.
|
Exhibit No. |
Description |
| 99.1 | Press Release of Flexion Therapeutics, Inc. dated July 10, 2017. |
Flexion Therapeutics Inc ExhibitEX-99.1 2 d423100dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Flexion Therapeutics to Hold Investor & Analyst Day Today – Management to discuss the latest plans for the potential launch of ZilrettaTM – Clinical experts to share perspectives on Zilretta – Company to introduce new pipeline candidate (FX101) BURLINGTON,…To view the full exhibit click here
About Flexion Therapeutics, Inc. (NASDAQ:FLXN)
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
